Patents by Inventor Jiangwei Zhang

Jiangwei Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
    Patent number: 12257251
    Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: March 25, 2025
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang
  • Use of BI853520 in cancer treatment
    Patent number: 12121519
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: October 22, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • Combined use of IN10018 and PLD
    Patent number: 12115160
    Abstract: The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
    Type: Grant
    Filed: August 24, 2023
    Date of Patent: October 15, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Jun Jiang, Shuang Xie, Jiangwei Zhang, Zaiqi Wang
  • Combination of BI853520 with chemotherapeutic drugs
    Patent number: 12097200
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: September 24, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20240307395
    Abstract: The present invention relates to a method for treating a tumor such as a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang, Xuebin Liu
  • Use of BI853520 in cancer treatment
    Patent number: 12064431
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: August 20, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • Use of BI853520 in cancer treatment
    Patent number: 12059421
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: August 13, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
    Publication number: 20240261285
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: April 11, 2024
    Publication date: August 8, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
    Publication number: 20240024319
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 25, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • COMBINED USE OF IN10018 AND PLD
    Publication number: 20230390289
    Abstract: The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: December 7, 2023
    Inventors: Jun Jiang, Shuang Xie, Jiangwei Zhang, Zaiqi Wang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20230372340
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION
    Publication number: 20230364088
    Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 16, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG, Jun JIANG
  • USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION
    Publication number: 20230145356
    Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 17, 2020
    Publication date: May 11, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG, Jun JIANG
  • COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
    Publication number: 20230079055
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 16, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20230000867
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 5, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG, Jun JIANG, Baoyuan ZHANG
  • MODULATION OF HSD17B13 EXPRESSION
    Publication number: 20210000906
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a liver disease, metabolic disease, or cardiovascular disease or disorder, including but not limited to NASH, in an individual.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 7, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan F. Murray, Jiangwei Zhang, Huynh-Hoa Bui
  • Single-side modified ?-Anderson-type heteropolymolybdate organic derivatives
    Patent number: 10759819
    Abstract: The present disclosure provides a single-side modified ?-Anderson-type heteropolymolybdate organic derivative having an anionic moiety with a general formula represented by: ?-{[RC(CH2O)3]M(OH)3Mo6O18}3?; ? represents a non-planar folded structure; R=substituted or unsubstituted phenyl, CnH2nX (n is an integer from 0 to 22; X?H, OH, NH(CH2)3SO3H, NHCH2COOH, NH2, or NO2); M=Cr3+. The single-side modified ?-Anderson-type heteropolymolybdate organic derivative can be prepared under hydrothermal conditions.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 1, 2020
    Assignee: PETROCHINA COMPANY LIMITED
    Inventors: Jianhui Lou, Yongge Wei, Bin Ding, Jiangwei Zhang, Pingmei Wang, Jin Zhang, Xiangfei Geng, Zheyu Wei, Baoliang Peng, Lipeng He
  • Single-Side Modified Beta-Anderson-Type Heteropolymolybdate Organic Derivatives
    Publication number: 20190352320
    Abstract: The present disclosure provides a single-side modified ?-Anderson-type heteropolymolybdate organic derivative having an anionic moiety with a general formula represented by: ?-{[RC(CH2O)3]M(OH)3Mo6O18}3?; ? represents a non-planar folded structure; R=substituted or unsubstituted phenyl, CnH2nX (n is an integer from 0 to 22; X=H, OH, NH(CH2)3SO3H, NHCH2COOH, NH2, or NO2); M=Cr3+. The single-side modified ?-Anderson-type heteropolymolybdate organic derivative can be prepared under hydrothermal conditions.
    Type: Application
    Filed: May 15, 2019
    Publication date: November 21, 2019
    Inventors: Jianhui Luo, Yongge Wei, Bin Ding, Jiangwei Zhang, Pingmei Wang, Jin Zhang, Xiangfei Geng, Zheyu Wei, Baoliang Peng, Lipeng He